@inbook{51f81f0805424028a9c6291e6b21ec68,
title = "CHAPTER 8: Muscarinic Receptors Allosteric Modulation",
abstract = "This chapter describes recent activity in the advancement of ligands and therapeutic lead compounds for the allosteric modulation of the muscarinic receptors and their potential utility as therapies for central nervous system (CNS) disorders. The chapter reviews the activity over the past five years of allosteric modulation of the muscarinic receptor subtypes M1 and M4, along with giving a brief overview of the M5 subtype. Due to concerns about off-target effects and toxicity with orthosteric modulators, much attention has concentrated on positive and negative allosteric modulators of these receptors in order to identify more selective lead compounds. Recent efforts have afforded a variety of improvements in potency and selectivity and pharmacokinetic properties that warrant further investigation and optimization.",
author = "Melancon, {Bruce J.} and Hopkins, {Corey R.}",
note = "Publisher Copyright: {\textcopyright} The Royal Society of Chemistry 2017.",
year = "2017",
doi = "10.1039/9781782629276-00175",
language = "English (US)",
series = "RSC Drug Discovery Series",
publisher = "Royal Society of Chemistry",
number = "56",
pages = "175--193",
editor = "Dario Doller",
booktitle = "Allosterism in Drug Discovery",
address = "United Kingdom",
edition = "56",
}